BioMarin Pharmaceutical Inc. (BIT:1BMRN)
49.63
0.00 (0.00%)
At close: Aug 13, 2025, 5:30 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
NAGLAZYME | 479.58M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
NAGLAZYME Growth | 9.04% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
ALDURAZYME | 183.89M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
ALDURAZYME Growth | 65.31% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
KUVAN | 120.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
KUVAN Growth | -24.64% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
FIRDAPSE | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
FIRDAPSE Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Royalty and Other | 44.47M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Royalty and Other Growth | -1.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
VIMIZIM | 739.78M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
VIMIZIM Growth | 9.65% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
BRINEURA | 169.08M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
BRINEURA Growth | 2.80% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
PALYNZIQ | 355.05M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
PALYNZIQ Growth | 18.01% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
VOXZOGO | 735.09M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
VOXZOGO Growth | 37.64% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
ROCTAVIAN | 26.07M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
ROCTAVIAN Growth | 218.56% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Royalty and Other | 44.47M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Royalty and Other Growth | -1.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Royalty and Other | 44.47M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Royalty and Other Growth | -1.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Royalty and Other | 44.47M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Royalty and Other Growth | -1.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States | 924.81M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States Growth | 22.23% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe | 829.03M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Growth | 19.28% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Latin America | 378.08M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Latin America Growth | 13.97% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rest of World Revenue (Pre-Q3 2024) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rest of World Revenue (Pre-Q3 2024) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 677.52M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 47.38% |
Log In |
Log In |
Log In |
Log In | Upgrade
|